Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy

Pierachille Santus,1 Maurizio Rizzi,2 Dejan Radovanovic,1 Andrea Airoldi,2 Andrea Cristiano,2 Rosalynn Conic,3 Stephen Petrou,4 Paolo Daniele Maria Pigatto,5 Nicola Bragazzi6, Delia Colombo6,7 Mohamad Goldust,8 and Giovanni Damiani3,9,10

1 Department of Biomedical Sciences L. Sacco, University of Milan, Milan, Italy
2 Respiratory Unit, Center for Sleep and Respiratory Disorders “Luigi Sacco” University Hospital, Milan, Italy
3 Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA
4 Department of Emergency Medicine, Good Samaritan Hospital Medical Center, New York, USA
5 Clinical Dermatology, Department of Biomedical, Surgical and Dental Sciences, IRCCS Galeazzi Orthopaedic Institute, University of Milan, 20126 Milan, Italy
6 Department of Health Sciences (DISSAL), School of Public Health, University of Genoa, 16132 Genoa, Italy
7 Department of Pharmacology, University of Milan, Milan, Italy
8 Mazandaran University of Medical Sciences, Sari, Iran
9 Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Unità Operativa di Dermatologia, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy
10 Young Dermatologists Italian Network (YDIN), GISED, Bergamo, Italy

Correspondence should be addressed to Giovanni Damiani; dr.giovanni.damiani@gmail.com

Received 23 June 2018; Revised 25 July 2018; Accepted 12 August 2018; Published 23 September 2018

Academic Editor: Dimitrios P. Bogdanos

Copyright © 2018 Pierachille Santus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Psoriasis is a chronic inflammatory systemic disease characterized by a wide range of comorbidities. Respiratory comorbidities are currently poorly characterized and with discordant results. The systemic state of inflammation caused by psoriasis acts de novo on respiratory tissues and amplifies preexisting inflammation from asthma or chronic obstructive pulmonary disease. Because the lungs act as a gas exchanger between the internal and external environment, the impact of chronic psoriasis inflammation may be easily assessed through the analysis of exhaled breath. The fraction of exhaled nitric oxide test (FeNO) is a potential noninvasive solution that can provide quantitative and qualitative indices of respiratory airway inflammation. FeNO is routinely used to screen and manage asthmatic patients. Recent pilot studies contain encouraging data that underscore its possible use with systemic inflammatory nonpulmonary diseases, such as psoriasis. FeNO may therefore be a useful tool to evaluate underestimated airway inflammation and at the same time globally evaluate the impact of systemically antipsoriatic therapies.

1. Introduction

Psoriasis (PS) is a chronic inflammatory systemic disease [1–4], characterized by scaling and erythematous plaques. It affects 2-3% of the present population [5]. From its relapsing remitting behaviour to related comorbidities, many bodies of evidence have proposed the idea that psoriasis extends beyond the skin [6]. Literature has shown PS-systemic inflammation is associated with higher risk of developing depression [7], cardiovascular events [8], diabetes [9], and
obstructive sleep apnea syndrome (OSAS) [10, 11]. Respiratory comorbidities are currently poorly characterized with conflicting findings [12–14]. Difficulties in assessing lung comorbidities in PS patients may be categorized into two main groups: (1) low compliance of PS patients to be extensively assessed [15]; (2) lack of a validated noninvasive, inexpensive, convenient tool. Educating patients that psoriasis not only affects the skin but also targets joints [16], entheses [17, 18], and the entire body by maintaining a chronic inflammatory status can help resolve problems with patient compliance. Creating a noninvasive assessment tool for potential lung comorbidities is the main focus of this review. Multiple epidemiological studies outline a possible correlation between PS and respiratory diseases [12–14]. They highlight an increased risk of asthma, chronic obstructive pulmonary disease (COPD), and airway infections in PS patients [14]. These diseases share common inflammatory pathogenic pathways with other psoriasis comorbidities [8]. Although the exact mechanism of PS comorbidities is still unclear, the most accepted hypothesis is that proinflammatory cytokines spill over through the blood from active psoriatic plaques, causing inflammation in distant tissues [19–21]. Each tissue responds in a specific way to the insult, such as atherosclerosis in the coronary and carotid vessel [22]. In addition, genetically predisposed individuals [23], whose proinflammatory cytokines trigger long distance inflammation, may exhibit consolidation and auto-maintenance [24]. This pathogenic theory designated as the “psoriatic march” was postulated by Boehncke. It attempts to explain the epidemiological correlation of psoriasis and cardiovascular comorbidities linked by a mechanism driven by systemic inflammation [24]. This idea could theoretically be applicable to all PS comorbidities, including respiratory. In fact, recent literature has described impaired lung function in psoriatic patients exhibiting lower mean Force Expiratory Volume in the 1st second (FEV1)/Force Vital Capacity (FVC) ratios and Forced Expiratory Flow (FEF) 25-75% [25]. Biological data confirms this theory, stating there is an increased tissue sensitivity to several proinflammatory cytokines including tumour necrosis factor-α (TNFα) and interleukin-1 (IL-1) [26]. This has been observed in psoriatic plaques and the blood of PS patients [26]. These cytokines act locally, in an autocrine or paracrine way, to maintain endocrine-like behaviour. If present in high enough concentration cytokines may also manifest endocrine-like behaviour, causing inflammation in other body areas [27]. This includes the airways through nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling transcription of several key enzymes, such as the inducible form of nitric oxide synthase (iNOS) which produces nitric oxide (NO) [28]. Because the lungs act as a gas exchanger between the internal and external environment, the impact of chronic psoriasis inflammation may be assessed by the analysis of fraction of exhaled nitric oxide (FeNO). FeNO could provide a quantitative and qualitative indicator of respiratory airway inflammation [29], as it is routinely used to screen and manage asthmatic patients [30]. Pilot studies have highlighted the possible use of FeNO in systemic inflammatory nonpulmonary diseases [Table 1] [31–34], such as psoriasis. In this review, we describe the rationale and possible applications of FeNO in the management of PS.

### Table 1: Fractions of exhaled nitric oxide display increased levels in autoimmune and inflammatory systemic disease.

| DISEASE                                      | FENO   | STUDIES                                      |
|----------------------------------------------|--------|----------------------------------------------|
| Psoriasis                                    | ↑      | Malerba M, et al. [19]                       |
| Juvenile idiopathic arthritis                | ↑      | Doğrul D, et al. [31]                        |
| Systemic sclerosis                           | ↑      | Guillen-Del Castillo A, et al. [32]          |
| Sarcoidosis                                  | ↑      | Choi J, et al. [33]                          |
| Intestinal bowel disease (IBD)               | ↑      | Furlano RI, et al. [34]                      |

2. Asthma and Psoriasis

Previous studies suggested a possible link between asthma and psoriasis [12–14]. Furthermore, asthma may be considered an umbrella term that groups different patterns of airway inflammation: paucigranulocytic (<3% eosinophils, <64% neutrophils) and eosinophilic (>3% eosinophils, <64% neutrophils) without increased total cell counts, neutrophilic (<3% eosinophils, >64% neutrophils) and mixed granulocytic (>3% eosinophils, >64% neutrophils) [63]. Although Th2 cells have a well-defined role in eosinophilic inflammation initiated by releasing IL-4, IL-5, and IL-13 and Th1 and Th17 cells may also lead to the neutrophilic response by releasing IL-6, IL-12, IL-17, and IL-23 [64]. IL-23 itself has been suggested to mediate neutrophilic antigen-mediated recruitment and at the same time eosinophilic recruitment via Th2 in the airways [65]. The pathophysiology is also enriched by several overlapping genetic risk loci that link psoriasis to asthma [66–68]. A recent meta-analysis described that asthma risk in PS patients is higher and that patients >50 years old have the highest risk [69], due to the increased duration of long-term inflammation in the airways.

Nadeem et al. have recreated in a mouse model the coexistence of psoriasis and asthma by triggering psoriasis with topical application of imiquimod and asthma by sensitizing mice airways with cockroach extract [70]. Mice treated in this manner had an increased count of both neutrophils and eosinophils in the airways, suggesting that psoriasis may
increase airway inflammatory pattern [70]. This hypothesis was ultimately confirmed in these mice by the increased number of both Th17 and Th2-specific cells as identified by STAT3-RORC and GATA3 [70]. Interestingly a topical inhibitor of STAT3 decreased both Th17 and Th2 counts, suggesting that Th17 have a prominent role in triggering and modulating inflammation in both the skin and the lung [70]. A unique case reports IL-12/IL-23 inhibitors as effective in treating a patient affected by both psoriasis and asthma [71].

3. COPD and Psoriasis

The relationship between COPD and psoriasis is highlighted by two distinct meta-analyses that suggest an association between these two chronic inflammatory diseases [72, 73]. In particular Ungprasert et al. found that COPD in PS patients has an odds ratio of 1.45 (95% CI, 1.21-1.73) by evaluating a total of 7 studies and 331,347 patients [74–80]. Recently Wu and colleagues analysed I10.729 incidental cases of psoriasis and their comorbidities, clustering the entire sample in 4 classes; one which manifests a propensity to develop COPD and hypertension [81]. Despite the nature of immune system dysfunction in COPD remaining largely unknown, the crosstalk between innate and adaptive immunity has been shown previously to lead to increased severity [82]. Dysfunctional neutrophils chemoattraction lead to a premature diapedesis and neutrophilic elastase release that inhibits dendritic cells (DCs) maturation, increased mucin production, and decreased lung function [83]. The active respiratory epithelium releases MIP3/CL20 that informs and recruits Th17 and DCs [84]. In fact, in COPD, as well as in psoriasis, patients demonstrate an imbalance between Th17 and Treg, a finding confirmed by Wang and colleagues [84]. High levels of Th17 cells in small airway associate with poor function; in particular, IL-17A and IL-17F trigger and lead to development of neutrophilic airway inflammation [83]. This inflammatory pattern was also tested by Nadeem and colleagues who found that psoriasis triggers and is triggered by airway inflammation [70].

4. Exhaled Nitric Oxide (FeNO) Measurement

All NO synthase (NOS) isoenzymes convert L-arginine to L-citrulline with the generation of NO [85]. Constitutive NOS includes neuronal-NOS (nNOS or nNOS), endothelial-NOS (eNOS or eNOS), and mitochondrial-NOS (mNOS) [86, 87]. Inducible-NOS (iNOS) is expressed only in response to inflammatory and infectious triggers, producing large quantities of NO independently by calcium ion influx [88]. NO in the lungs is mainly produced by the alveoli epithelium and moves to the lumen driven by a concentration gradient. Consequently, FeNO is a flow-dependent measure [89]. The gold standard to assess FeNO is an inline method by which expiration is continuously sampled by an NO analyser. The resultant NO profile versus time or exhaled volume together with other exhalation variables (airway flow rate and/or pressure) is captured and displayed in real-time [89]. The patient inhales NO sampled air through a preassessed calibrated mouthpiece up to total lung capacity and then exhalates without holding their breath, as a breath hold would increase NO diffusion time from the airway wall to air and cause inaccurate results. It is for this same reason that low exhalation flow rates increase FeNO and high ones decrease it. It is common practice to display the pressure or expiratory flow rate to the subject, who is subsequently asked to maintain a positive mouthpiece pressure between 5 and 20 cmH2O to avoid nasal backflow of NO. A nose clip should also be avoided. Correct exhalation should last for >6 seconds (exhaled volume of at least 0.3 L at 50 mL/s) resulting in a single-breath NO profile (exhaled NO versus time plot) that consists of a washout phase followed by a plateau of at least 3 seconds. Repeated exhalations should be performed to obtain at least 2 values that agree within 10% of each other. Exhaled NO is then calculated as the mean of the two values. At least 30 seconds of tidal breathing off the circuit should elapse between exhalations [89]. FeNO obtained at 50 mL/s is a reliable source of the production of NO in respiratory airways, but there is no simple surrogate for determining the distal airway/alveolar concentration of NO (CANO), because FeNO must be obtained at multiple expiratory flow rates in order to be able to distinguish between the airway production and CANO: 30, 50, 100, and 200 mL/s [89]. Physiological and pathological conditions responsible for affecting FeNO measurements are reviewed and summarized in Table 2 [35–62]. According to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines, non-disease related factors influencing FeNO values are very young age (children), female sex (during menses or pregnancy), respiratory maneuvers (performing spirometry reduces FeNO), airway calibrating, some food and beverages, smoking (which reduces FeNO chronically and acutely), infections, hypoxia, exercise, and medications directly related to NO synthesis [89] (Table 2).

5. Nitric Oxide as a Mediator of Inflammatory Disease

Initial pulmonary changes are not always evident from a classic spirometry exam. In these conditions, FeNO provides an added value in the early diagnosis of an active inflammatory process [90]. FeNO has already been accepted in literature as an indirect marker of airway inflammation used to monitor/manage asthma and prevent its recurrences [91]. Measurement of FeNO has been also suggested as a biomarker of several nonpulmonary diseases (Table 1). Different theories have been suggested to explain why FeNO measurement should be increased in nonpulmonary diseases: (1) leukocyte priming and subsequent homing in embryonically related tissues (as between lung and bowel) [92, 93] and (2) proinflammatory cytokine release from lesioned tissue driven by blood to the lung [19]. An increasing body of evidence has claimed the clinical usefulness of this method in daily practice as well as in nonrespiratory diseases. Decreased FeNO in heart disease may suggest a failure in compensatory circulatory mechanisms, as found in congestive heart failure (CHF) [93] and pulmonary hypertension (PH). Low alveolar NO is considered a marker of hypoxia and endothelial dysfunction since hypoxia induces vasoconstriction [85]. The
### Table 2: Factors that may perturb FeNO measurements.

| FRACTION OF EXHALED NITRIC OXIDE (FENO) AND INTERFERRAL FACTORS | INCREASED FENO | DECREASED FENO | STUDIES |
| --- | --- | --- | --- |
| **Drug intake:** | (i) ACE inhibitors [35]; (ii) Papaverin [36]; (iii) Sodium nitroprusside [37]. | (i) Oxymetazoline [38]; (ii) NOS inhibitors [39]. | Sumino H, et al [35], Holden WE, et al [36], Runer T, et al [37], Sippel JM, et al [38], Yates DH, et al [39] |
| **Food and Beverages:** | (i) Nitrite/Nitrate-enriched food [40]; (ii) Arginine ingestion [40]. | (i) Curcumin and Resveratrol [41]. | McKnight GM, et al [40], Tenero L, et al [41] |
| **Environmental factors:** | (i) NO in air [42]; (ii) Calibration of FeNO analyser [43]; (iii) Occupational exposure to ozone, chlorine dioxide, formaldehyde [44]; | (i) Calibration of FeNO analyser [42]; | Binding N, et al [42], Franklin P, et al [43], Nightingale JA, et al [44] |
| **Physiological and pathological conditions and tests:** | (i) Airway Infections [45]; (ii) Lung neoplasia [46]; (iii) COPD [47]; (iv) Asthma [47]; (v) Systemic inflammatory conditions [48]; (vi) Chronic cough [49]. | (i) Tabagism [50]; (ii) Alcohol ingestion [51]; (iii) Chronic hypoxia [52]; (iv) Spirometry [53]; (v) Sputum induction [54]; (vi) Hypothermia [55]; (vii) Hyperventilation [53]; (viii) Physical exercise [56]; (ix) Menstrual cycle [57]; (x) Childhood [58]; (xi) Female gender [59]. | Kharitonov SA, et al [45], Liu PF, et al [46], Chen FJ, et al [47], Uppalapati A, et al [48], Song WJ, et al [49], Xu X, et al [50], Yates DH, et al [51], Dimov PK, et al [52], Deykin A, et al [53], Piacentini A, et al [54], Pendergast DR, et al [55], Phillips CR, et al [56], Kharitonov SA, et al [57], Tang S, et al [58], Murri V, et al [59] |

Sickle anemia [60], circadian rhythm [61], and pregnancy [62] are actually under consideration.

Cohen RF, et al [60], Saito J, et al [61], Nittner-Marszalska M, et al [62]
same explanatory mechanism is also described in obstructive sleep apnea syndrome (OSAS) where the alveolar component (CANO) is decreased [94], most likely subsequent to hypoxia [95]. Although CANO is decreased in OSAS, overall FeNO is increased because the main component is produced by the upper airways [96]. Conversely, increased FeNO levels might reflect excessive vasodilation as in hepatopulmonary syndrome (HPS) [97] or be the consequence of a systemic high level of inflammatory cytokines as in Hodgkin's Lymphoma (HL) [98], systemic sclerosis (SSc) [99], Crohn's disease (CD) [91], and other inflammatory bowel diseases (IBDs) [92]. Perturbation of metabolism, such as in obesity, that leads to a proinflammatory condition may elevate FeNO as demonstrated by the correlation between body mass index (BMI) and FeNO [47].

6. Psoriasis and Nitric Oxide Production

The skin of psoriatic patients, both lesional and nonlesional, globally presents increased proinflammatory cytokine patterns, characterized by the presence of IFNγ, TNFα, IL-8, IL-1 and IL-6, and IL-17 [100–102]. NO is a labile mediator and can be detected at high levels in psoriatic plaques in the presence of these cytokines which results in overtranscription of iNOS and arginase through NFκB signaling [103]. Although at low concentrations NO is physiologically and continuously released by the respiratory epithelium and endothelium [28], to enable high concentrations of NO release a stimulus is needed [104, 105]. Psoriasis causes endothelial vessel dysfunction [104] and an accumulation of asymmetrical dimethyl arginine (ADMA), NOS inhibitors [106], and decreased free NO content in blood [107]. At the same time, blood transports the locally produced proinflammatory cytokines that trigger inflammation in distant tissues. The production of NO is increased in many skin diseases such as contact dermatitis, atopic dermatitis, and psoriasis [108–111]. The increased levels of NO suggest a role for this molecule in maintaining the proinflammatory microenvironment of psoriasis. NO is described as capable of initiating psoriasis mainly by releasing calcitonin gene-related peptide and substance P. These substances are considered to play important roles in the pathogenesis of psoriasis by inducing the production of adhesion molecules, keratinocyte hyperproliferation, mast cell degranulation, vasodilatation, and chemotaxis of neutrophils [112]. NO stimulates epithelial cells to release chemokines and growth factors which appear to be important for keratinocyte proliferation and angiogenesis [113]. In psoriatic lesions, an overexpression of iNOS is associated with a compensatory increase of arginine-1 enzyme which may reduce the NO availability [114–120]. On the other hand, direct measurements of NO production in psoriatic lesions did not show any evidence of competitive inhibition [117]. In psoriasis patients, serum NO levels correlated with the Psoriasis Area Severity Index (PASI) [121] highlighting an important relationship between active disease and an increased level of FeNO [19]. Recently, a positive correlation between the PASI score and FeNO values has also been found at a flow of 50 mL s\(^{-1}\), which would reveal the presence of subclinical respiratory inflammation in patients with psoriasis [19]. Persistent inflammation may produce a change in airway microstructure, decreasing dynamicity and functionality [122]. Microstructure change may reflect a loss of function and a risk of developing respiratory disease. A demonstration of chronic subclinical inflammation could be useful in identifying the underlying biological mechanism contributing to the aetiology of chronically compromised respiratory function such as COPD [122] or OSAS [10]. It is noteworthy that psoriasis, COPD, and OSAS present some common risk factors such as obesity, smoking, physical inactivity, and metabolic syndrome. The vast majority of current studies are not prospective which prevents a clear establishment of a causal relationship.

7. Conclusion

Measurement of FeNO is an easy to perform, noninvasive, reproducible test which requires relatively low collaboration. The current available data seem to suggest that the proinflammatory systemic status due to psoriasis [123] may involve also the respiratory tract [124]. From this perspective, FeNO should be a part of screening moderate-to-severe psoriasis patients. The studies published to date encourage its introduction in daily practice and its inclusion into research of new biomarkers [19, 125]. Further studies are needed to validate existing data on FeNO measurement and to firmly establish it as part of standard screening in patients with moderate-to-severe psoriasis.

**Abbreviations**

- ATS: American Thoracic Society
- BMI: Body mass index
- CANO: Alveolar concentration of NO
- CD: Crohn's disease
- CHF: Congestive heart failure
- COPD: Chronic obstructive pulmonary disease
- ERS: European Respiratory Society
- FeNO: Fraction of exhaled nitric oxide
- FVC: Force vital capacity
- FEV1: Force expiratory volume in the 1st second
- FEF: Forced expiratory flow
- HL: Hodgkin's Lymphoma
- HPS: Hepato-pulmonary syndrome
- IBD: Inflammatory bowel disease
- IL: Interleukin
- NFκB: Nuclear factor kappa-light-chain-enhancer of activated B cells
- NO: Nitric oxide
- NOS: Inducible form of nitric oxide synthase: (i) e: endothelial, (ii) i: inducible, (iii) m: mitochondrial, and (iv) n: neuronal
- OSAS: Obstructive sleep apnea syndrome
- PASI: Psoriasis Area Severity Index
- PH: Pulmonary hypertension
- PS: Psoriasis
- SSc: Systemic sclerosis
- TNF: Tumour necrosis factor-α.
Data Availability

We searched Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE, Embase, and Web of Science.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Pierachille Santus, Maurizio Rizzi, and Dejan Radovanovic wrote the manuscript; Andrea Airoldi, Paolo Daniele Maria Pigatto, and Andrea Cristiano did the bibliographic research; Stephen Petrou edited the language; and Giovanni Damiani directed the overall steps.

Acknowledgments

The authors would like to acknowledge Mrs. Danielle Corrigan for language assistance and Miss Maria Sala for creating the tables. Rosalynn Conic is supported by the P50 AR070590-01A1 National Institute of Health T32 grant; Rosalynn Conic and the authors acknowledge Mrs. Danielle Corrigan for language assistance and Miss Maria Sala for creating the tables. Rosalynn Conic is supported by the P50 AR070590-01A1 National Institute of Health T32 grant; Rosalynn Conic and the authors acknowledge Mrs. Danielle Corrigan for language assistance and Miss Maria Sala for creating the tables.

References

[1] C. M. Hedrich, "Shaping the spectrum - From autoinflammation to autoimmunity," Clinical Immunology, vol. 165, pp. 21-28, 2016.

[2] G. Damiani, C. Franchi, P. Pigatto et al., "Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new direct-acting antiviral agents," World Journal of Hepatology, vol. 10, no. 2, pp. 329–336, 2018.

[3] M. Fiore, S. Leone, A. E. Maroalo, E. Berti, and G. Damiani, "Liver Illness and Psoriatic Patients," BioMed Research International, vol. 2018, Article ID 340983, 12 pages, 2018.

[4] G. Damiani, E. Berti, P. D. M. Pigatto et al., "Benchmarking Stem cells and transplantation in psoriasis," Journal of Stem Cell Research and Therapy, vol. 8, Article ID 1000416, 2018.

[5] S. K. Raychaudhuri, E. Mavarakis, and S. P. Raychaudhuri, "Diagnosis and classification of psoriasis," Autoimmunity Reviews, vol. 13, no. 4-5, pp. 490–495, 2014.

[6] M. Versini, P.-Y. Jeandel, E. Rosenthal, and Y. Shoenfeld, "Obesity in autoimmune diseases: not a passive bystander," Autoimmunity Reviews, vol. 13, no. 9, pp. 981–1000, 2014.

[7] R. T. Lewinsson, I. A. Vallerand, M. W. Lowerison et al., "Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study," Journal of Investigative Dermatology, vol. 137, no. 4, pp. 828–835, 2017.

[8] H. B. Naik, B. Natarajan, E. Stansky et al., "Severity of Psoriasis Associates with Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 12, pp. 2667–2676, 2015.

[9] R. S. Azfar, N. M. Seminara, D. B. Shin, A. B. Troxel, D. J. Margolis, and J. M. Gelfand, "Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis," Archives of Dermatology, vol. 148, no. 9, pp. 995–1000, 2012.

[10] A. Egeberg, U. Khalid, G. H. Gislason, L. Mallbris, L. Skov, and P. R. Hansen, "Psoriasis and sleep apnea: a danish nationwide cohort study," Journal of Clinical Sleep Medicine, vol. 12, no. 5, pp. 663–671, 2016.

[11] Y. M. F. Andersen, A. Egeberg, G. H. Gislason, L. Skov, and J. P. Thyssen, "Burden of respiratory comorbidities in patients with atopic dermatitis and psoriasis," British Journal of Dermatology, vol. 177, no. 4, pp. e45–e46, 2017.

[12] H.-Y. Fang, W.-C. Liao, C.-L. Lin, C.-H. Chen, and C.-H. Kao, "Association between psoriasis and asthma: A population-based retrospective cohort analysis," British Journal of Dermatology, vol. 172, no. 4, pp. 1066–1071, 2015.

[13] A. S. Lonnberg, L. Skov, A. Skytte et al., "Asthma in patients with psoriasis," British Journal of Dermatology, vol. 172, no. 6, pp. 1660–1661, 2015.

[14] L. Kao, C. Lee, S. Liu, M. Tsai, H. Lin, and J. D. Chalmers, "Psoriasis and the risk of pneumonia: a population-based study," PLoS ONE, vol. 9, no. 12, Article ID e106077, 2014.

[15] E. Lubrano, F. Cantini, A. Costanzo et al., "Measuring psoriatic disease in clinical practice. An expert opinion position paper," Autoimmunity Reviews, vol. 14, no. 1, pp. 864–874, 2015.

[16] L. I. Sakkas and D. P. Bogdanos, "Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data," Autoimmunity Reviews, vol. 16, no. 1, pp. 10–15, 2017.

[17] M. S. Chimienti, E. Ballanti, C. Perricone, P. Cipriani, R. Giacomelli, and R. Perricone, "Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways," Autoimmunity Reviews, vol. 12, no. 5, pp. 599–606, 2013.

[18] K. M. Klaassen, M. J. Ploegmakers, P. C. van de Kerkhof, W. M. Klein, and M. C. Pasch, "Subclinical enthesitis in nail psoriasis patients: a case-control study," JDDG: Journal der Deutschen Dermatologischen Gesellschaft, vol. 15, no. 4, pp. 405–412, 2017.

[19] G. Damiani, A. Radaeli, A. Olivini, P. Calvara-Pinton, and M. Malerba, "Increased airway inflammation in patients with psoriasis," British Journal of Dermatology, vol. 175, no. 4, pp. 797–799, 2016.

[20] M. Malerba, A. Radaeli, A. Olivini et al., "Exhaled nitric oxide as a biomarker in COPD and related comorbidities," BioMed Research International, vol. 2014, Article ID 271918, 2014.

[21] M. Malerba, G. Damiani, A. Radaeli, B. Ragnoli, A. Olivini, and P. G. Calzavara-Pinton, "Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma," British Journal of Dermatology, vol. 173, no. 6, pp. 1544–1545, 2015.

[22] S. Santilli, D. R. Kast, I. Grozdev et al., "Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center," Journal of Translational Medicine, vol. 14, no. 1, p. 217, 2016.

[23] Y. Lu, H. Chen, P. Nikamo et al., "Association of cardiovascular and metabolic disease genes with psoriasis," Journal of Investigative Dermatology, vol. 133, no. 3, pp. 836–839, 2013.

[24] W.-H. Boehncke, S. Boehncke, A.-M. Tobin, and B. Kirby, "The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity," Experimental Dermatology, vol. 20, no. 4, pp. 303–307, 2011.
[25] D. D. Balci, E. Celik, S. Genc, M. M. Çelik, and M. U. Inan, "Impaired Pulmonary Function in Patients with Psoriasis," *Dermatology*, vol. 232, no. 6, pp. 664–667, 2016.

[26] E. A. Dowlatshahi, E. A. M. Van Der Voort, L. R. Arends, and T. Nijsten, "Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis," *British Journal of Dermatology*, vol. 169, no. 2, pp. 266–282, 2013.

[27] C. Garlanda, C. A. Dinarello, and A. Mantovani, "The interleukin-1 family: back to the future," *Immunology*, vol. 39, no. 6, pp. 1003–1018, 2013.

[28] S. Birkenfeld, J. Dreither, D. Weitzman, and A. Cohen, "Coeliac disease associated with psoriasis," *British Journal of Dermatology*, vol. 16, no. 6, pp. 1331–1334, 2009.

[29] S. Karrasch, K. Linde, G. Rucker et al., "Accuracy of FENO for diagnosing asthma: A systematic review," *Thorax*, vol. 72, no. 2, pp. 109–116, 2017.

[30] R. K. Meena, D. Raj, R. Lodha, and S. K. Kabra, "Fractional exhaled nitric oxide for identification of uncontrolled asthma in children," *Indian Pediatrics*, vol. 53, no. 4, pp. 307–310, 2016.

[31] D. Doğruel, M. Yılmaz, G. Bingöl, D. U. Altıntaş, and S. Gençer Kendirli, "Fraction of exhaled nitric oxide as a predictor in juvenile idiopathic arthritis progression," *Clinical Rheumatology*, vol. 36, no. 3, pp. 541–546, 2017.

[32] A. Guillen-del Castillo, S. Sánchez-Vidaurre, C. P. Simeón-Aznar, M. J. Cruz, V. Fonollosa-Pla, and X. Muñoz, "Prognostic role of exhaled breath condensate pH and fraction exhaled nitric oxide in systemic sclerosis related interstitial lung disease," *Archivos de Bronconeumología*, vol. 53, no. 3, pp. 120–127, 2017.

[33] J. Choi, L. A. Hoffman, J. M. Sethi, T. G. Zullo, and K. F. Gibson, "Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis: A pilot feasibility study," *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, vol. 26, no. 2, pp. 98–109, 2009.

[34] R. I. Furlan, P. Basek, P. Müller et al., "Pulmonary function test abnormalities in pediatric inflammatory bowel disease," *Respiration*, vol. 90, no. 4, pp. 279–286, 2015.

[35] H. Sumino, T. Nakamura, T. Kanda et al., "Effect of enalapril on exhaled nitric oxide in normotensive and hypertensive subjects," *Hypertension*, vol. 36, no. 6, pp. 934–940, 2000.

[36] W. E. Holden, J. P. Wilkins, M. Harris, H. A. Milczuk, and G. D. Giraud, "Temperature conditioning of nasal air: Effects of vasoactive agents and involvement of nitric oxide," *Journal of Applied Physiology*, vol. 87, no. 4, pp. 1260–1265, 1999.

[37] T. Runer, A. Cervin, S. Lindberg, and R. Uddman, "Nitric oxide is a regulator of mucociliary activity in the upper respiratory tract," *Otolaryngology—Head and Neck Surgery*, vol. 119, no. 3, pp. 278–287, 1998.

[38] J. M. Sippel, G. D. Giraud, and W. E. Holden, "Nasal administration of the nitric oxide synthase inhibitor L-NAME induces daytime somnolence," *Sleep*, vol. 22, no. 6, pp. 768–786, 1999.

[39] D. H. Yates, S. A. Kharitonov, R. A. Robbins, P. S. Thomas, and P. J. Barnes, "Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide," *American Journal of Respiratory and Critical Care Medicine*, vol. 152, no. 3, pp. 892–896, 1995.

[40] G. M. McKnight, L. M. Smith, R. S. Drummond, C. W. Duncan, M. Golden, and N. Benjamín, "Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans," *Gut*, vol. 40, no. 2, pp. 211–214, 1997.

[41] L. Tenero, M. Piazza, L. Zanoni, A. Bodini, D. Peroni, and G. L. Piacentini, "Antioxidant supplementation and exhaled nitric oxide in children with asthma," *Allergy and Asthma Proceedings*, vol. 37, no. 1, pp. e8–e13, 2016.

[42] N. Binding, W. Muller, P. A. Czeschinski, and U. Witting, "NO chemiluminescence in exhaled air: Interference of compounds from endogenous or exogenous sources," *European Respiratory Journal*, vol. 16, no. 3, pp. 499–503, 2000.

[43] P. Franklin, P. Dingle, and S. Stick, "Raised exhaled nitric oxide in healthy children is associated with formaldehyde levels," *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 5, pp. 1757–1759, 2000.

[44] J. A. Nightingale, D. F. Rogers, and P. J. Barnes, "Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects," *Thorax*, vol. 54, no. 12, pp. 1061–1069, 1999.

[45] S. A. Kharitonov, D. Yates, and P. J. Barnes, "Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections," *European Respiratory Journal*, vol. 8, no. 2, pp. 295–297, 1995.

[46] P. Liu, D. Zhao, Y. Qi et al., "The clinical value of exhaled nitric oxide in patients with lung cancer," *The Clinical Respiratory Journal*, vol. 12, no. 1, pp. 23–30, 2018.

[47] F. J. Chen, X. Y. Huang, Y. L. Liu et al., "Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD," *International Journal of Chronic Obstructive Pulmonary Disease*, vol. 11, pp. 2385–2390, 2016.

[48] A. Uppalapati, S. Gogineni, and J. R. Espiritu, "Association between Body Mass Index (BMI) and fraction of exhaled nitric oxide (FeNO) levels in the National Health and Nutrition Examination Survey (NHANES) 2007–2010," *Obesity Research & Clinical Practice*, vol. 10, no. 6, pp. 652–658, 2016.

[49] W.-J. Song, H. J. Kim, J.-S. Shim et al., "Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and meta-analysis," *The Journal of Allergy and Clinical Immunology*, vol. 140, no. 3, pp. 701–709, 2017.

[50] X. Xu, H. Hu, G. D. Kearney, H. Kan, G. Carrillo, and X. Chen, "A population-based study of smoking, serum cotinine and exhaled nitric oxide among asthmatics and a healthy population in the USA," *Inhalation Toxicology*, vol. 28, no. 14, pp. 724–730, 2016.

[51] D. H. Yates, S. A. Kharitonov, R. A. Robbins, P. S. Thomas, and P. J. Barnes, "The effect of alcohol ingestion on exhaled nitric oxide," *European Respiratory Journal*, vol. 9, no. 6, pp. 1130–1133, 1996.

[52] P. K. Dimov, B. I. Marinov, I. S. Ilchev, Z. Z. Taralov, and S. Kostianev, "Evaluation of Acute Exogenous Hypoxia Impact on the Fraction of Exhaled Nitric Oxide in Healthy Males," *Folia Medica*, vol. 57, no. 3–4, pp. 230–234, 2015.

[53] A. Deykin, A. F. Massaro, E. Coulson, J. M. Drazen, and E. Israel, "Exhaled nitric oxide following repeated spirometry or repeated plethysmography in healthy individuals," *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 4, pp. 1237–1240, 2000.

[54] G. L. Piacentini, A. Bodini, S. Costella, L. Vicentini, Y. Suzuki, and A. L. Boner, "Exhaled nitric oxide is reduced after sputum induction in asthmatic children," *Pediatric Pulmonology*, vol. 29, no. 6, pp. 430–433, 2000.

[55] D. R. Pendergast, J. A. Krasney, and D. Deroberts, "Effects of immersion in cool water on lung-exhaled nitric oxide at rest and..."
 during exercise," *Respiration Physiology*, vol. 115, no. 1, pp. 73–81, 1999.

[56] C. R. Phillips, G. D. Giraud, and W. E. Holden, "Exhaled nitric oxide during exercise: site of release and modulation by ventilation and blood flow," *Journal of Applied Physiology*, vol. 80, no. 6, pp. 1865–1871, 1996.

[57] S. A. Khattar, R. B. Logan-Sinclair, C. M. Busset, and E. A. Shinbourne, "Peak expiratory nitric oxide differences in men and women: Relation to the menstrual cycle," *British Heart Journal*, vol. 72, no. 3, pp. 243–249, 1994.

[58] S. Tang, Y. Xie, C. Yuan, X. Sun, and Y. Cui, "Fractional exhaled nitric oxide for the diagnosis of childhood asthma: a systematic review and meta-analysis," *Clinical Reviews in Allergy & Immunology*, pp. 1–10, 2016.

[59] V. Murri, F. Antoniazzi, M. Piazza et al., "Lung Function in Women with Idiopathic Central Precocious Puberty: A Pilot Study," *Hormone Research in Paediatrics*, vol. 87, no. 2, pp. 95–102, 2017.

[60] R. T. Cohen, M. Rodeghier, F. J. Kirkham et al., "Exhaled nitric oxide: Not associated with asthma, symptoms, or spirometry in children with sickle cell anemia," *The Journal of Allergy and Clinical Immunology*, vol. 138, no. 5, pp. 1338–1343, 2016.

[61] J. Saito, D. Gibeon, P. Macedo, A. Menzies-Gow, P. K. Bhavsar, and K. F. Chung, "Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control," *European Respiratory Journal*, vol. 43, no. 2, pp. 474–484, 2014.

[62] M. Nittner-Marszalska, J. Liebhart, R. Pawłowicz et al., "Fractioned exhaled nitric oxide (FENO) is not a sufficiently reliable test for monitoring asthma in pregnancy," *Nitril Oxide: Biology and Chemistry*, vol. 33, pp. 56–63, 2013.

[63] S. Svenningsen and P. Nair, "Asthma endotypes and an overview of targeted therapy for asthma," *Frontiers in Medicine*, vol. 4, no. 158, 2017.

[64] R. Halwani, A. Sultana, A. Vazquez-Tello, A. Jamhawi, A. A. Al-Marsi, and S. Al-Muhsen, "Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma," *Journal of Asthma & Allergy Educators*, vol. 5, no. 9, pp. 893–904, 2017.

[65] H. Nakajima and K. Hirose, "Role of IL-23 and Th17 Cells in the Immunopathogenesis of Psoriasis," *Frontiers in Investigational Drugs*, vol. 7, no. 1, pp. 65–75, 1998.

[66] P. Ungprasert, N. Srivali, and C. Thongprayoon, "Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis," *Journal of Dermatological Treatment*, vol. 27, no. 4, pp. 316–321, 2016.

[67] X. Li, L. Kong, F. Li et al., "Association between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis," *PLoS ONE*, vol. 10, no. 12, Article ID e0145221, 2015.

[68] D. J. Pearce, A. E. Morrison, K. B. Higgins et al., "The comorbid state of psoriasis patients in a university dermatology practice," *Journal of Dermatological Treatment*, vol. 16, no. 5–6, pp. 319–323, 2005.

[69] J. Dreher, D. Weitzman, J. Shapiro, B. Davidovici, and A. D. Cohen, "Psoriasis and chronic obstructive pulmonary disease: A case-control study," *British Journal of Dermatology*, vol. 159, no. 4, pp. 956–960, 2008.

[70] Y. Wu, D. Mills, and M. Bala, "Psoriasis: cardiovascular risk factors and other disease comorbidities," *Journal of Drugs in Dermatology*, vol. 7, pp. 373–377, 2008.

[71] N. Al-Mutairi, S. Al-Farag, A. Al-Mutairi, and M. Al-Shitawy, "Comorbidity associated with psoriasis: An experience from the Middle East," *The Journal of Dermatology*, vol. 37, no. 2, pp. 146–155, 2010.

[72] G.-A. Vena, G. Altomare, and F. Ayala, "Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database," *European Journal of Dermatology*, vol. 20, pp. 599–598, 2010.

[73] T.-F. Tsai, T.-S. Wang, S.-T. Hung et al., "Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan," *Journal of Dermatological Science*, vol. 63, no. 1, pp. 40–46, 2011.

[74] H. Yeung, J. Takeshita, N. N. Mehta et al., "Psoriasis severity and the prevalence of major medical comorbidity: a population-based study," *JAMA Dermatology*, vol. 149, no. 10, pp. 1173–1179, 2013.

[75] C.-Y. Wu, H.-Y. Hu, and C.-P. Li, "Comorbidity profiles of psoriasis in Taiwan: a latent class analysis," *PLoS One*, vol. 13, Article ID e0192537, 2018.

[76] T. A. Bhat, L. Panzica, S. G. Kalathil, and Y. Thanavala, "Immune dysfunction in patients with chronic obstructive pulmonary disease," *Annals of the American Thoracic Society*, vol. 12, Suppl 2, pp. S169–S175, 2015.

[77] L. Ni and C. Dong, "Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease," *Frontiers in Immunology*, vol. 9, p. 1431, 2018.

[78] X. Wang, C. Zhang, and G. Huang, "Resveratrol inhibits dysfunction of dendritic cells from chronic obstructive pulmonary disease patients through promoting miR-34," *International Journal of Clinical and Experimental Pathology*, vol. 8, pp. 5145–5152, 2015.

[79] A. Malinovschi, A. Van Muylem, S. Michiels, and A. Michils, "FeNO as a predictor of asthma control improvement after starting inhaled steroid treatment," *Nitril Oxide: Biology and Chemistry*, vol. 40, pp. 110–116, 2014.

[80] K. L. Davis, E. Martin, I. V. Turko, and F. Murad, "Novel effects of nitric oxide," *Annual Review of Pharmacology and Toxicology*, vol. 41, pp. 203–236, 2001.

[81] P. Ghafooriifar and C. Richter, "Nitric oxide synthase activity in mitochondria," *FEBS Letters*, vol. 418, no. 3, pp. 291–296, 1997.

[82] D. Salvemini and M. H. Marino, "Inducible nitric oxide synthase and inflammation," *Expert Opinion on Investigational Drugs*, vol. 7, no. 1, pp. 65–75, 1998.
[122] A. T. Dinh-Xuan, I. Annesi-Maesano, P. Berger et al., "Contribution of exhaled nitric oxide measurement in airway inflammation assessment in asthma. A position paper from the French Speaking Respiratory Society," Revue des Maladies Respiratoires, vol. 32, no. 2, pp. 193–215, 2015.

[123] V. Della Valle, M. Maggioni, and C. Carrera, "A mysterious abdominal pain during active psoriasis," Internal and Emergency Medicine, vol. 13, no. 6, pp. 889–892, 2017.

[124] M. Confalonieri, N. Di Meo, G. Damiani et al., "An adalimumab-induced late-onset immune reconstitution inflammatory syndrome treated with adalimumab," Giornale Italiano di Dermatologia e Venereologia, vol. 153, no. 1, pp. 129-130, 2018.

[125] F. Asaad, M. Fiore, A. Alfieri et al., "Saliva as a Future Field in Psoriasis Research," BioMed Research International, vol. 2018, Article ID 7290913, 6 pages, 2018.